Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;17(1):1357-1362.
doi: 10.3892/ol.2018.9663. Epub 2018 Nov 5.

Variation of Nicotinic Subtype α7 and Muscarinic Subtype M3 Acetylcholine Receptor Expression in Three Main Types of Leukemia

Affiliations
Free PMC article

Variation of Nicotinic Subtype α7 and Muscarinic Subtype M3 Acetylcholine Receptor Expression in Three Main Types of Leukemia

Tawit Suriyo et al. Oncol Lett. .
Free PMC article

Abstract

Cholinergic receptors, such as α7-nicotinic acetylcholine receptor (α7-nAChR) and M3-muscarinic acetylcholine receptor (M3-mAChR), have been demonstrated to serve a significant role in the proliferation, differentiation and apoptosis of leukemic cells. However, the expression of these receptors in samples from patients with leukemia remains unclear. The present study aimed to determine the expression of M3-mAChR and α7-nAChR in the bone marrow or peripheral blood of 51 patients with leukemia, including acute myeloid leukemia (AML; n=33), acute lymphoblastic leukemia (ALL; n=13), and chronic myeloid leukemia (CML; n=5). Peripheral blood mononuclear cells (PBMCs) were also isolated from healthy subjects (n=5) for comparison. Western blot analysis was performed to determine the protein expression profiles, and a pattern of decreased α7-nAChR levels in patients with leukemia was observed. Among the leukemia types, the lowest expression of α7-nAChR and M3-mAChR were identified in patients with T-cell ALL/lymphoma (T-ALL). CML exhibited the highest level of M3-mAChR, which was significantly different from APL and AML-M4, yet not from healthy subjects (P<0.05). Therefore, different expression profiles of α7-nACR and M3-mAChR were detected amongst the leukemia types. Collectively, the present study supports the potential role of cholinergic signaling in mediating leukemogenesis. However, further studies in larger cohorts are required to validate these findings.

Keywords: M3-muscarinic acetylcholine receptor; acute lymphoblastic leukemia; acute myeloid leukemia; chronic myeloid leukemia; α7-nicotinic acetylcholine receptor.

Figures

Figure 1.
Figure 1.
Expression levels of α7-nAChR in patients with leukemia. (A) Representative immunoblots of α7-nAChR in the three main types of leukemia, including five subtypes of AML, two subtypes of ALL, and CML. GAPDH was used as the loading control. (B) The ratio of α7-nAChR to GAPDH was determined by densitometric analysis. Data are presented as the means ± standard deviation. The number of cases in each group is presented in parentheses on the × axis. P<0.05 was considered to indicate a statistically significant difference. α7-nAChR, nicotinic subtype α7 acetylcholine receptors; AML-M0, AML with minimal differentiation; AML-M1, AML without maturation; AML-M2, AML with maturation; APL, acute promyelocytic leukemia; AML-M4, acute myelomonocytic leukemia; CML, chronic myeloid leukemia; T-ALL, T lymphoblastic leukemia/lymphoma; B-ALL, B lymphoblastic leukemia/lymphoma.
Figure 2.
Figure 2.
Expression levels of M3-mAChR in patients with leukemia. (A) Representative immunoblots of M3-mAChR in the three main types of leukemia, including five subtypes of AML, two subtypes of ALL, and CML. (B) Ratio of M3-mAChR to GAPDH as determined by densitometric analysis. Data are presented as the means ± standard deviation. The number of cases in each group is presented in parentheses at the × axis. P<0.05 was considered to indicate a statistically significant difference. M3-mAChR, muscarinic subtype M3 acetylcholine receptors; AML-M0, AML with minimal differentiation; AML-M1, AML without maturation; AML-M2, AML with maturation; APL, acute promyelocytic leukemia; AML-M4, acute myelomonocytic leukemia; CML, chronic myeloid leukemia; T-ALL, T lymphoblastic leukemia/lymphoma; B-ALL, B lymphoblastic leukemia/lymphoma.

Similar articles

See all similar articles

LinkOut - more resources

Feedback